OXNARD, Calif. – May 1, 2018 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it received an investment of $500,000 from a strategic partner to advance its cannabinoid-based drug delivery product line. This investment comes from a pharmaceutical partner in the form of a convertible loan.
“This is an important step in building out our cannabinoid program, which targets therapies in a wide range of disease indications,” said Rob Davidson, CEO of CURE Pharmaceutical. “Our goal is to expedite our first cannabinoid-based drug delivery treatment using our patented, CUREfilm™.”
Cannabinoids are chemical compounds found in plants, such as cannabis (phytocannabinoids), synthesized by cells of the human body (endocannabinoids) or synthesized in a laboratory (biosynthetic cannabinoids) that interact with the body’s endocannabinoid system. The endocannabinoid system is recognized as an important modulatory system in the function of the brain, endocrine, and immune tissues. Cannabinoids, and other molecules that interact with the endocannabinoid system, have shown promise for treating a broad array of indications, such as pain, nausea, anxiety, inflammation and other central nervous system disorders.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company’s business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.